| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
104,690,000 |
| Market
Cap: |
101.88(B) |
| Last
Volume: |
336,854 |
Avg
Vol: |
765,410 |
| 52
Week Range: |
$692.45 - $993.95 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 150 |
| Guru Rank Value : 6.9 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
167,577 |
238,336 |
281,337 |
440,071 |
| Total Sell Value |
$163,474,195 |
$228,361,384 |
$264,009,288 |
$375,002,857 |
| Total People Sold |
6 |
14 |
16 |
18 |
| Total Sell Transactions |
13 |
43 |
61 |
121 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fenimore Christopher R. |
SVP Controller |
• – – |
2021-08-20 |
4 |
OE |
$179.13 |
$2,418,255 |
D/D |
13,500 |
32,520 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2021-08-19 |
4 |
AS |
$660.03 |
$6,600,300 |
I/I |
(10,000) |
21,178 |
|
-2% |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2021-08-18 |
4 |
AS |
$650.03 |
$130,006,000 |
D/D |
(200,000) |
304,746 |
|
2% |
|
| Coles N Anthony |
Director |
– • – |
2021-08-18 |
4 |
AS |
$650.00 |
$3,315,000 |
D/D |
(5,100) |
902 |
|
2% |
|
| Coles N Anthony |
Director |
– • – |
2021-08-18 |
4 |
OE |
$345.47 |
$1,761,897 |
D/D |
5,100 |
6,002 |
|
- |
|
| Vagelos P Roy |
Director |
– • – |
2021-08-18 |
4 |
AS |
$650.04 |
$6,525,752 |
I/I |
(10,039) |
37,747 |
|
2% |
|
| Coles N Anthony |
Director |
– • – |
2021-08-17 |
4 |
AS |
$650.00 |
$585,000 |
D/D |
(900) |
902 |
|
-1% |
|
| Coles N Anthony |
Director |
– • – |
2021-08-17 |
4 |
OE |
$345.47 |
$310,923 |
D/D |
900 |
1,802 |
|
- |
|
| Murphy Andrew J |
EVP Research |
• – – |
2021-08-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,645 |
55,705 |
|
- |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2021-08-16 |
4 |
AS |
$625.25 |
$30,781,138 |
D/D |
(49,227) |
887,483 |
|
1% |
|
| Bassler Bonnie L |
Director |
– • – |
2021-08-16 |
4 |
AS |
$630.00 |
$767,970 |
D/D |
(1,219) |
891 |
|
1% |
|
| Bassler Bonnie L |
Director |
– • – |
2021-08-16 |
4 |
OE |
$376.69 |
$459,185 |
D/D |
1,219 |
2,110 |
|
- |
|
| Schleifer Leonard S |
President & CEO |
• • – |
2021-08-16 |
4 |
AS |
$615.54 |
$6,243,614 |
I/I |
(10,000) |
31,178 |
|
1% |
|
| Sing George L |
Director |
– • – |
2021-08-16 |
4 |
S |
$627.50 |
$627,500 |
I/I |
(1,000) |
2,050 |
|
-1% |
|
| Sing George L |
Director |
– • – |
2021-08-16 |
4 |
S |
$630.00 |
$444,150 |
D/D |
(705) |
43,858 |
|
-1% |
|
| Yancopoulos George |
President and Chief Scientific |
• • – |
2021-08-13 |
4 |
AS |
$625.00 |
$483,125 |
D/D |
(773) |
936,710 |
|
0% |
|
| Coles N Anthony |
Director |
– • – |
2021-08-13 |
4 |
AS |
$625.00 |
$1,250,000 |
D/D |
(2,000) |
902 |
|
0% |
|
| Coles N Anthony |
Director |
– • – |
2021-08-13 |
4 |
OE |
$345.47 |
$690,940 |
D/D |
2,000 |
2,902 |
|
- |
|
| Sing George L |
Director |
– • – |
2021-08-13 |
4 |
S |
$620.00 |
$310,000 |
D/D |
(500) |
44,563 |
|
-0% |
|
| Sing George L |
Director |
– • – |
2021-08-12 |
4 |
S |
$611.00 |
$611,000 |
D/D |
(1,000) |
45,063 |
|
-2% |
|
| Sing George L |
Director |
– • – |
2021-08-11 |
4 |
S |
$620.00 |
$186,000 |
I/I |
(300) |
3,050 |
|
0% |
|
| Sing George L |
Director |
– • – |
2021-08-11 |
4 |
S |
$620.00 |
$1,241,000 |
D/D |
(2,000) |
46,063 |
|
0% |
|
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
• – – |
2021-08-10 |
4 |
S |
$606.50 |
$4,040,105 |
D/D |
(6,603) |
26,931 |
|
-1% |
|
| Sing George L |
Director |
– • – |
2021-08-10 |
4 |
S |
$613.01 |
$1,596,010 |
D/D |
(2,600) |
48,063 |
|
-1% |
|
| Landry Robert E |
EVP Finance CFO |
• – – |
2021-08-10 |
4 |
AS |
$611.00 |
$328,593 |
D/D |
(537) |
25,903 |
|
1% |
|
1366 Records found
|
|
Page 21 of 55 |
|
|
11.86 (1.2%) 
